Published • loading... • Updated
Artiva to Discontinue Cell Therapy After Two Patient Deaths, Cut Workforce by 94%
The company cited two patient deaths and weaker-than-needed long-term response data as it ends the program and explores a possible merger or sale.
- On Tuesday, Artiva Biotherapeutics announced the discontinuation of its lead candidate AlloNK and initiated a strategic review following two patient deaths in a Phase 2a trial.
- The company halted development after two Grade 5 safety events and updated longer-term clinical data showed durability of response did not meet thresholds required to support continued development.
- Investigators assessed one death as likely related to fludarabine-associated neurotoxicity, while a second patient experienced sudden death assessed as unrelated to AlloNK or any treatment component.
- To preserve capital, Artiva will reduce its workforce by about 94%, affecting roughly 98 employees, while holding approximately $319.1 million in cash, cash equivalents, and investments as of September 30, 2026.
- Shares tumbled 30.5% on Tuesday following the announcement, as Artiva canceled its November 9 investor webcast and retained Leerink Partners to evaluate strategic alternatives.
Insights by Ground AI
12 Articles
12 Articles
GC Cell's U.S. partner, Artiva Biotherapeutics, has halted the development of its flagship cell therapy. This decision was made following two deaths during clinical trials and a failure to meet expectations regarding the sustainability of therapeutic effects in long-term follow-up. In response to this news, GC Cell's stock price fell by approximately 17% at one point during morning trading on the 28th compared to the previous trading day. Artiva…
Artiva discontinues cell therapy after two patient deaths, cuts ...
·London, United Kingdom
Read Full Article
Artiva to discontinue cell therapy after two patient deaths, cut workforce by 94%
Artiva Biotherapeutics said on Tuesday it would halt the development \u200bof an experimental cell therapy for certain autoimmune conditions \u2014 its lead candidate \u2014 after two patient deaths, \u200csending its shares slumping 32%.
·Salt Lake City, United States
Read Full ArticleCoverage Details
Total News Sources12
Leaning Left0Leaning Right2Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
